Celyad Oncology Announces June 2021 Conference Schedule
26 mai 2021 01h00 HE
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, May 26, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of...
Transparency notification received from Victory Capital Management Inc. (Article 14 §1 of the Law of 2 May 2007)
19 mai 2021 01h00 HE
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, May 19, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of...
Celyad Oncology to Present Data from Phase 1 IMMUNICY-1 Trial of Non-Gene Edited Allogeneic CAR T Candidate CYAD-211 in Relapsed/Refractory Multiple Myeloma at the European Hematology Association Virtual Congress
12 mai 2021 16h01 HE
|
Celyad Oncology SA
No Grade ≥ 3 treatment-related adverse events nor evidence of Graft-versus-Host disease reported from the completed first dose-level (DL1) cohort of Phase 1 dose-escalation IMMUNICY-1 trial evaluating...
Celyad Oncology Announces First Quarter 2021 Financial Results and Recent Business Highlights
06 mai 2021 16h01 HE
|
Celyad Oncology SA
Enrollment continues in second dose cohort of Phase 1 dose-escalation IMMUNICY-1 trial for lead shRNA-based allogeneic CAR T candidate, CYAD-211, for relapsed/refractory multiple myeloma (r/r MM);...
Transparency Notification Received from Tolefi SA (Article 14 §1 of the Law of 2 May 2007)
05 mai 2021 01h00 HE
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, May 05, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of...
Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
04 mai 2021 01h00 HE
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, May 04, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of...
Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
30 avr. 2021 01h00 HE
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, April 30, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of...
Celyad Oncology Appoints Dr. Charles Morris as Chief Medical Officer
19 avr. 2021 01h00 HE
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, April 19, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of...
Celyad Oncology Announces April 2021 Conference Schedule
01 avr. 2021 01h00 HE
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, April 01, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of...
Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
31 mars 2021 01h00 HE
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, March 31, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of...